Nesina and Death - a phase IV clinical study of FDA data

Summary:

Death is reported as a side effect among people who take Nesina (alogliptin benzoate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Amlodipine, and have Diabetes.

The study is created by eHealthMe based on reports of 2,291 people who have side effects when taking Nesina from the FDA, and is updated regularly.

What is Nesina?

Nesina has active ingredients of alogliptin benzoate. eHealthMe is studying from 2,297 Nesina users. Check the latest studies of Nesina.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

2,291 people reported to have side effects when taking Nesina.
Among them, 53 people (2.31%) died.

Among these 53 people:

How long have people been on Nesina when they died? *

What is the gender of people who died when taking Nesina? *

female: 54.35 %
male: 45.65 %

What is the age of people who died when taking Nesina? *

What are other drugs people take besides Nesina? *

What are other side effects people have before they died? *

Nausea (feeling of having an urge to vomit): 5 people, 9.43%
Fever: 4 people, 7.55%
Diarrhea: 4 people, 7.55%
Nasopharyngitis (inflammation of the nasopharynx): 3 people, 5.66%
Nausea And Vomiting: 3 people, 5.66%
Fistula (an abnormal connection or passageway between two): 3 people, 5.66%
Osteonecrosis Of Jaw (death of bone of jaw): 3 people, 5.66%
Back Pain: 3 people, 5.66%
Pneumonia Influenzal (the flu with pneumonia): 3 people, 5.66%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 3 people, 5.66%

What are the existing conditions these people have? *

Diabetes: 16 people, 30.19%
Type 2 Diabetes: 10 people, 18.87%
Constipation: 7 people, 13.21%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 6 people, 11.32%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 7.55%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 4 people, 7.55%
Gastric Ulcer (stomach ulcer): 4 people, 7.55%
Hyperlipidaemia (presence of excess lipids in the blood): 4 people, 7.55%
Metastases To Bone (cancer spreads to bone): 3 people, 5.66%
Diabetic Nephropathy (diabetic kidney disease): 3 people, 5.66%

* Approximation only. Some reports may have incomplete information.

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Nesina:

Nesina (2,297 reports)

Expand to all the drugs that have ingredients of alogliptin benzoate:

Death and drugs with ingredients of alogliptin benzoate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Nesina:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Death:

Death (3,107 drugs)

Browse all the conditions that are associated with Death:

Death (3,686 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on alogliptin benzoate (the active ingredients of Nesina) and Nesina (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.